Selenium in metabolic syndrome

The Effect of Selenium Supplementation on Glucose Homeostasis and Lipid Profile in Women with Metabolic Syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191109045372N1

Enrollment

Registered

2019-12-10

Start date

2017-12-22

Completion date

Unknown

Last updated

2019-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

METABOLIC SYNDROME. Metabolic syndrome

Interventions

Intervention 1: Intervention group: Thirty-five patients were included in the intervention group.Participants were delivered a 200 microgram selenium capsule made by 21st Century America Inc. purchase

Eligibility

Sex/Gender

Female

Age

20 Years to 49 Years

Inclusion criteria

Inclusion criteria: Were no consumption of antioxidant supplements NO underlying diseases including kidney diseases, hypothyroidism, digestive diseases, dyspepsia, etc. Not being in menopause Not having weight loss diet over the last six months Not taking any drugs affecting the level of blood lipids No pregnancy and breast-feeding

Exclusion criteria

Exclusion criteria: No willingness to continue the cooperation, pregnancy, not adhering to the study protocol, developing special diseases during the study were among the exclusion criteria. Note that patients taking insulin were also excluded.

Design outcomes

Primary

Measure	Time frame
FBS. Timepoint: The beginning of the study and the end of the study. Method of measurement: Biochemical.;Insulin. Timepoint: The beginning of the study and the end of the study. Method of measurement: Eliza.;HOMA-IR. Timepoint: The beginning of the study and the end of the study. Method of measurement: FORMULA.;QUICKI. Timepoint: The beginning of the study and the end of the study. Method of measurement: FORMULA.;TRIGLYCERIDE. Timepoint: The beginning of the study and the end of the study. Method of measurement: BIOCHEMICAL.;Total cholestrol. Timepoint: The beginning of the study and the end of the study. Method of measurement: Biochemical.;HDL cholestrol. Timepoint: The beginning of the study and the end of the study. Method of measurement: BIOCHEMICAL.;LDL cholestrol. Timepoint: The beginning of the study and the end of the study. Method of measurement: Formula.	—

Measure

Time frame

FBS. Timepoint: The beginning of the study and the end of the study. Method of measurement: Biochemical.;Insulin. Timepoint: The beginning of the study and the end of the study. Method of measurement: Eliza.;HOMA-IR. Timepoint: The beginning of the study and the end of the study. Method of measurement: FORMULA.;QUICKI. Timepoint: The beginning of the study and the end of the study. Method of measurement: FORMULA.;TRIGLYCERIDE. Timepoint: The beginning of the study and the end of the study. Method of measurement: BIOCHEMICAL.;Total cholestrol. Timepoint: The beginning of the study and the end of the study. Method of measurement: Biochemical.;HDL cholestrol. Timepoint: The beginning of the study and the end of the study. Method of measurement: BIOCHEMICAL.;LDL cholestrol. Timepoint: The beginning of the study and the end of the study. Method of measurement: Formula.

—

Secondary

Measure	Time frame
Body Mass Index. Timepoint: The beginning and the end of the study. Method of measurement: Weight (kg) / Height (m) to power 2.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZeinab Malekpour Shahraki

Esfahan University of Medical Sciences

msz_nut@yahoo.com+98 31 3792 3151

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026